MBRX Chief Science Officer Donald Picker Sells $66 of Stock

Donald Picker, the Chief Science Officer at MBRX, sold 21 shares of the company on June 22, 2026. The shares were sold at an average price of $3.12, bringing the total transaction value to $65.52. This transaction was not part of a pre-planned trading program.

Insider Buying and Selling at Moleculin Biotech, Inc.

On the same day, Donald Picker also bought 71 shares, while Walter Klemp, the CEO and President, sold 360 shares. Jonathan Foster, the Chief Financial Officer, sold 41 shares at $3.12 each but also bought 174 shares. These transactions highlight a mix of buying and selling among MBRX's top executives.

Other Institutional Activity in MBRX

Several institutional investors have made moves in MBRX. Sabby Management, LLC opened a new position with 75,021 shares worth about $171,798. Geode Capital Management, LLC increased its holdings by 17,191 shares, resulting in a 113.6% increase, bringing their total to 32,329 shares valued at approximately $74,033. Rockefeller Capital Management L.P. also boosted its stake by 4,203 shares, a 1928% increase, ending with 4,421 shares worth about $10,124.

Analysts Set New Price Targets

On March 24, 2026, HC Wainwright & Co. reiterated its buy rating for MBRX with a price target of $22.00. The firm has consistently maintained a positive outlook on the stock. The consensus among analysts remains favorable, with a strong buy recommendation and a mean target price reflecting optimism about MBRX's prospects.

Bottom Line

Donald Picker's recent sale is part of a series of insider transactions at MBRX, reflecting diverse strategies among the company's leadership. Institutional investors also show varied interest, with some significantly increasing their stakes. Analysts maintain a positive stance on MBRX, suggesting confidence in its future performance. Keep in mind that insider trades are typically reported after they occur and may not indicate future moves.